ESC 365 - A randomised, double-blind, placebo-controlled study to investigate the safety and tolerability of XXB750 in heart failure patients with reduced or mildly reduced ejection fraction

ESC Professional Premium Access

A randomised, double-blind, placebo-controlled study to investigate the safety and tolerability of XXB750 in heart failure patients with reduced or mildly reduced ejection fraction

Session: Smaller trials, trial updates, and other studies on heart failure (1)

Topic: Pharmacotherapy

Speaker: Doctor T. Hauser (Cambridge, US)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Doctor Thomas Hauser

Novartis Biomedical Research, Cambridge (United States of America)

1 presentation

0 follower

4 more presentations in this session

The effect of dapagliflozin on accelerometer-based measures of physical activity in heart failure: an exploratory analysis of the DETERMINE trials

Speaker: Doctor K. Docherty (Glasgow, GB)

Synchronized left ventricular pacing improves cardiac resynchronization therapy outcomes: insights from AdaptResponse

Speaker: Doctor D. Birnie (Ottawa, CA)

Catheter ablation in end-stage heart failure with atrial fibrillation: two-year follow-up of the CASTLE-HTx trial

Speaker: Professor C. Sohns (Bad Oeynhausen, DE)

Rapid detection of incident heart failure by artificial intelligence: lessons from the NIL-CHF trial

Speaker: Professor S. Stewart (Sydney, AU)

Access the full session

Smaller trials, trial updates, and other studies on heart failure (1)

Speakers: Doctor T. Hauser, Doctor K. Docherty, Doctor D. Birnie, Professor C. Sohns, Professor S. Stewart

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources